Search
DEEN
more info

Contact:
Phone:+49 0761 1514 440Fax:+49 0761 1514 460Email:info[at]falkfoundation.org

    Falk Gastro Review Journal

    Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

    Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

    The latest issues

    Edition 4/2024

    read more

    Edition 3/2024

    read more

    Edition 2/2024

    read more

    Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

    All articles

    Esophagus to Small Intestine

    Incidence and mortality in upper gastrointestinal cancer after negative endoscopy for gastroesophageal reflux disease

    Gastroenterology. 2022;162(2):431–8.e4

    Holmberg D, Santoni G, von Euler-Chelpin MC, Färkkilä M, Kauppila JH, Maret-Ouda J, Ness-Jensen E, Lagergren J

    Go to article

    Esophagus to Small Intestine

    Systematic review with meta-analysis: The effectiveness of either ustekinumab or vedolizumab in patients with Crohn’s disease refractory to anti-tumor necrosis factor

    Aliment Pharmacol Ther. 2022;55(4):380–8

    Parrot L, Dong C, Carbonnel F, Meyer A

    Go to article

    Esophagus to Small Intestine

    Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn’s disease

    Gastroenterology. 2022;162(2):495–508

    Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D’Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ

    Go to article

    Esophagus to Small Intestine

    Natural history and risk stratification of recurrent Crohn’s disease after ileocolonic resection: A multicenter retrospective cohort study

    Inflamm Bowel Dis. 2022;28(1):1–8

    Joustra VW, Duijvestein M, Mookhoek A, Bemelman W, Buskens C, Koželj M, Novak G, Hindryckx P, Mostafavi N, D’Haens G

    Go to article

    Colon to Rectum

    Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis

    Clin Gastroenterol Hepatol. 2022;20(1):105–15.e14

    Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D’Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG

    Go to article

    Colon to Rectum

    Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): A randomized, double-blind, double-dummy, phase 3 study

    Lancet Gastroenterol Hepatol. 2022;7(2):118–27

    Danese S, Colombel JF, Lukas M, Gisbert JP, D’Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group

    Go to article

    Colon to Rectum

    Use of contraceptives and risk of inflammatory bowel disease: A nested case-control study

    Aliment Pharmacol Ther. 2022;55(3):318–26

    Pasvol TJ, Bloom S, Segal AW, Rait G, Horsfall L

    Go to article

    Colon to Rectum

    Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα

    Gastroenterology. 2022;162(2):454–67

    Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group (RECOVER)

    Go to article

    Colon to Rectum

    Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: A report from the epi-IIRN

    Gut. 2022;71(2):287–95

    Gorelik Y, Freilich S, Gerassy-Vainberg S, Pressman S, Friss C, Blatt A, Focht G, Loewenberg Weisband Y, Greenfeld S, Kariv R, Lederman N, Dotan I, Geva-Zatorsky N, Shen-Orr SS, Kashi Y, Chowers Y; Israeli IBD research nucleus (IIRN)

    Go to article